Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imeglimin - Poxel

Next Previous
Drug Profile

Imeglimin - Poxel

Alternative Names: EMD-387008; Imeglimin hydrochloride - Poxel; Imeglimine - Poxel; PXL 008; RVT-1501; TWYMEEG

Latest Information Update: 02 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA
  • Developer Poxel; Sumitomo Pharma
  • Class Amines; Antihyperglycaemics; Small molecules; Triazines; Urologics
  • Mechanism of Action Insulin secretion stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • No development reported Kidney disorders

Most Recent Events

  • 24 Nov 2025 Imeglimin - Poxel is available for licensing in Asia, China as of 24 Nov 2025. https://www.poxelpharma.com/en_us
  • 08 Apr 2025 Pharmaceuticals and Medical Devices Agency approves Imeglimin for treatment of Type II diabetes mellitus to include patients with moderate to severe renal impairment in Japan
  • 31 Mar 2025 Poxel has patent protection for imeglimin in Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top